<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://www.w3.org/2005/Atom">
<title>MED: Otolaryngology Papers</title>
<link href="http://hdl.handle.net/2144/2460" rel="alternate"/>
<subtitle/>
<id>http://hdl.handle.net/2144/2460</id>
<updated>2013-05-21T08:44:54Z</updated>
<dc:date>2013-05-21T08:44:54Z</dc:date>
<entry>
<title>Prognostic Outcomes of Tall Cell Variant Papillary Thyroid Cancer: A Meta-Analysis</title>
<link href="http://hdl.handle.net/2144/3095" rel="alternate"/>
<author>
<name>Jalisi, Scharukh</name>
</author>
<author>
<name>Ainsworth, Tiffiny</name>
</author>
<author>
<name>LaValley, Michael</name>
</author>
<id>http://hdl.handle.net/2144/3095</id>
<updated>2012-01-12T07:01:58Z</updated>
<published>2010-07-26T00:00:00Z</published>
<summary type="text">Prognostic Outcomes of Tall Cell Variant Papillary Thyroid Cancer: A Meta-Analysis
Jalisi, Scharukh; Ainsworth, Tiffiny; LaValley, Michael
Objective. To evaluate the prognosis of tall cell variant (TCV) compared to usual variant (UV) papillary thyroid cancer by comparing disease-related mortality and recurrence data from published studies. Methods. Ovid MEDLINE keyword search using "tall cell variant papillary thyroid cancer" was used to identify studies published in English that calculated disease-related mortality and recurrence rates for both TCV and UV. Results. A total of 131 cases of tall cell variant papillary thyroid cancer were reviewed. The combined odds ratio of recurrence for TCV compared to UV is 4.50 with a 95% confidence interval from 2.90 to 6.99. For disease-related mortality, the combined odds ratio for TCV was compared to UV of 14.28 with a 95% confidence interval from 8.01 to 25.46. Conclusion. Currently published data suggests that TCV is a negative prognostic indicator in papillary thyroid cancer and requires aggressive therapy. This meta-analysis provides the largest prognostic data series on TCV in the literature and clearly identifies the need for accurate pathological identification of TCV and its further study as an independent prognostic factor.
</summary>
<dc:date>2010-07-26T00:00:00Z</dc:date>
</entry>
<entry>
<title>Minimal and Direct Access Surgery in Urology</title>
<link href="http://hdl.handle.net/2144/2658" rel="alternate"/>
<author>
<name>Repassy, D. L.</name>
</author>
<author>
<name>Frang, D.</name>
</author>
<author>
<name>Jako, G. J.</name>
</author>
<id>http://hdl.handle.net/2144/2658</id>
<updated>2011-12-30T07:00:43Z</updated>
<published>2011-12-29T00:00:00Z</published>
<summary type="text">Minimal and Direct Access Surgery in Urology
Repassy, D. L.; Frang, D.; Jako, G. J.
An alternative method to laparoscopic surgery has been developed for urological procedures. The surgery is minimal access because the length of the single skin incision ranges from 3–6 cm depending on the type of operation. It is direct access because the surgeon sees the operative area directly and stereoscopically by eye without video-optical support. The procedure requires a special open-lumen retractorscope (JakoscopeTM) with a high intensity fiberoptic light system and modified standard hand instruments. Among the procedures performed nephrectomy, ureterolithotomy, prostatic adenomectomy, spermatic vein ligation and others have been performed. The kidney procedures have been operated retroperitoneally through a minilumbotomy incision. The procedures are simple, rapid and the instruments are inexpensive. The postoperative pain and morbidity are comparable to the laparoscopic approach.
</summary>
<dc:date>2011-12-29T00:00:00Z</dc:date>
</entry>
</feed>
